SLFN11 and small cell lung carcinoma: In patients with recurrent SCLC, SLFN11-positive tumors(H score cutoff ≥1 defined SLFN11 positive) exhibited better responses to the combination therapy of temozolomide and veliparib, with significantly prolonged PFS and OS (37).